List view / Grid view
9 November 2016 | By Niamh Louise Marriott, Digital Content Producer
In this newly-created role, Dr Antonijevic will be responsible for advancing the clinical development of vasopharm’s lead ongoing program, VAS203...
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Vasopharm's ronopternin (VAS203) will be evaluated for its safety and efficacy as the first patient is enrolled into the nostra phase III (NO Synthase in TRAumatic Brain Injury) trial – a clinical study to assess whether the drug can be used as a initial treatment for moderately to severely injured…
21 January 2016 | By Victoria White
Vasopharm has designed a Phase III registration study in Europe of VAS203 in in moderate to severe traumatic brain injury...
